Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: A randomized, double-blind, active-controlled, multicenter study

Lipids in Health and Disease

Volumn 11, Issue , 2012, Pages

  Hing Ling, Paul ^a   Civeira, Fernando ^b   Dan, Andrei ^c   Hanson, Mary E ^d   Massaad, Rachid ^e   De Tilleghem, Celine ^e   Milardo, Christopher ^d   Triscari, Joseph ^d  

^a MONASH UNIVERSITY MALAYSIA   (Malaysia)

^b HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^c V Babes National Institute of Pathology   (Romania)

^d MERCK RESEARCH LABORATORIES   (United States)

^e Merck Sharp and Dohme   (Belgium)

Author keywords

Atorvastatin; Ezetimibe simvastatin; High cardiovascular risk; Lipid lowering; Primary hypercholesterolemia

Indexed keywords

ATORVASTATIN; EZETIMIBE PLUS SIMVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; AZETIDINE DERIVATIVE; C REACTIVE PROTEIN; EZETIMIBE; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; LIPID; PYRROLE DERIVATIVE; SIMVASTATIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GALLBLADDER DISEASE; GASTROINTESTINAL SYMPTOM; HEPATITIS; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; LIPIDS; MALE; MIDDLE AGED; PYRROLES; SIMVASTATIN; TREATMENT OUTCOME;

EID: 84856358934     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-11-18     Document Type: Article

References (20)

1. Perspectives on low-density lipoprotein cholesterol goal achievement. Catapano AL, Curr Med Res Opin 2009 25 431 447 10.1185/03007990802631438 19192988
2. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, Couture P, Dufour R, Fodor G, Francis GA, Grover S, Gupta M, Hegele RA, Lau DC, Leiter L, Lewis GF, Lonn E, Mancini GB, Ng D, Pearson GJ, Sniderman A, Stone JA, Ur E, Can J Cardiol 2009 25 567 579 10.1016/S0828-282X(09)70715-9 19812802
3. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Expert panel on detection evaluation and treatment of high blood cholesterol in adults, JAMA 2001 285 2486 2497 10.1001/jama.285.19.2486 11368702
4. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Catapano AL, Reiner Z, De Backer G, et al. Atherosclerosis 2011 217 3 46 10.1016/j.atherosclerosis.2011. 06.028 21882396
5. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U, Eur J Cardiovasc Prev Rehabil 2009 16 121 137 10.1097/HJR.0b013e3283294b1d 19287307
6. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Pearson TA, Laurora I, Chu H, Kafonek S, Arch Intern Med 2000 160 459 467 10.1001/archinte.160.4.459 10695686 (Pubitemid 30112269)
7. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets. McCormack T, Harvey P, Gaunt R, Allgar V, Chipperfield R, Robinson P, Int J Clin Pract 2010 64 1052 1061 10.1111/j.1742-1241.2010.02429.x 20487050
8. Ezetimibe: cholesterol lowering and beyond. Bays HE, Neff D, Tomassini JE, Tershakovec AM, Expert Rev Cardiovasc Ther 2008 6 447 470 10.1586/14779072.6.4.447 18402536
9. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. van Roeters Lennep HW, Liem AH, Dunselman PH, Dallinga-Thie GM, Zwinderman AH, Jukema JW, Curr Med Res Opin 2008 24 685 694 10.1185/030079908X273273 18226326 (Pubitemid 351428979)
10. Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. Barrios V, Amabile N, Paganelli F, Chen JW, Allen C, Johnson-Levonas AO, Massaad R, Vandormael K, Int J Clin Pract 2005 59 1377 1386 10.1111/j.1368-5031.2005.00714.x 16351668 (Pubitemid 43922623)
11. Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus. Constance C, Westphal S, Chung N, Lund M, McCrary SC, Johnson-Levonas AO, Massaad R, Allen C, Diabetes Obes Metab 2007 9 575 584 10.1111/j.1463-1326.2007.00725.x 17451425 (Pubitemid 47018521)
12. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Goldberg RB, Guyton JR, Mazzone T, Weinstock RS, Polis A, Edwards P, Tomassini JE, Tershakovec AM, Mayo Clin Proc 2006 81 1579 1588 10.4065/81.12.1579 17165637 (Pubitemid 44871902)
13. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). Robinson JG, Ballantyne CM, Grundy SM, Hsueh WA, Parving HH, Rosen JB, Adewale AJ, Polis AB, Tomassini JE, Tershakovec AM, Am J Cardiol 2009 103 1694 1702 10.1016/j.amjcard.2009.05.003 19539078
14. Update on the efficacy and safety of combination ezetimibe plus statin therapy. Toth PP, Catapano A, Tomassini JE, Tershacoved AM, Clinical Lipidology 2010 5 651 653 10.2217/clp.10.58
15. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. Conard SE, Bays HE, Leiter LA, Bird SR, Rubino J, Lowe RS, Tomassini JE, Tershakovec AM, Am J Cardiol 2008 102 1489 1494 10.1016/j.amjcard.2008.09.075 19026302
16. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Leiter LA, Bays H, Conard S, Bird S, Rubino J, Hanson ME, Tomassini JE, Tershakovec AM, Am J Cardiol 2008 102 1495 1501 10.1016/j.amjcard.2008.09.076 19026303
17. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J, Am Heart J 2005 149 464 473 10.1016/j.ahj.2004.11.023 15864235 (Pubitemid 40585409)
18. Ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency. Viigimaa M, Vaverkova H, Farnier M, Averna M, Missault L, Hanson ME, Dong Q, Shah A, Brudi P, Lipids Health Dis 2010 9 127 10.1186/1476-511X-9-127 21050476
19. LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD. McKenney J, Ballantyne CM, Feldman TA, Brady WE, Shah A, Davies MJ, Palmisano J, Mitchel YB, MedGenMed 2005 7 3 16614625
20. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J, Am J Cardiol 2004 93 1487 1494 10.1016/j.amjcard.2004.02.060 15194018 (Pubitemid 38749204)